CKD is an important co-morbidity of cardiovascular disease
CYTX received US Patent No. 8,404,229 (the '229 patent) for methods of treating renal diseases using adipose-derived regenerative cells ("ADRCs"). The '229 patent covers treatment of a broad range of renal disorders, including acute kidney disease (AKD) and chronic kidney disease (CKD). The '229 patent also covers multiple means of delivering the ADRCs, including to the kidney directly, to the renal vasculature or to the renal parenchyma.
The Bottom Line: The '229 patent complements CYTX's previously issued European Patent No. 1 778 834 (the '834 patent) directed to the treatment of renal disorders. Similar to the '229 US patent, the '834 European patent covers treatment of a broad range of renal disorders, including AKD and CKD. The '834 patent is effective in the United Kingdom, Germany, France, Netherlands, Spain, Belgium, Sweden, and select other EU countries. CYTX's platform technology and recent European approval of Intravase® for intravascular delivery will allow them to explore related indications without compromising the cardiovascular focus and core indications.
CYTX closed at $2.52 and is UP +$0.01 or +0.39% - expect small volume but a penny or two on a fastly closing holy week.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.